Drug Trial Radar · NCT01238861
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Last checked: Nov 20, 2026Latest source record: Nov 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
964
Actual
Start
Dec 2010
Primary completion
Mar 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- MedImmune Ltd
- First posted
- Nov 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
Conditions
- Asthma
Interventions
Benralizumab 2 mgBiological
EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
Benralizumab 20 mgBiological
EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
Benralizumab 100 mgBiological
EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
PlaceboOther
EOS+ and EOS- participants received two placebo injections subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) ParticipantsTime frame: Week 1 up to Week 52
Locations
74 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Diego, California
Research Site
Stockton, California
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Waterbury, Connecticut
Research Site
Kissimmee, Florida
Research Site
Tampa, Florida
Research Site
Stockbridge, Georgia
Research Site
Normal, Illinois
Research Site
Baltimore, Maryland
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Bellevue, Nebraska
Research Site
Summit, New Jersey
Research Site
Rochester, New York
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Blue Bell, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Warwick, Rhode Island
Research Site
Boerne, Texas
Research Site
San Antonio, Texas
Research Site
Seattle, Washington
Research Site
Caba, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Santa Fe, Argentina
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Juiz de Fora, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
Pleven, Bulgaria
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.